305 related articles for article (PubMed ID: 3276825)
1. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer.
Friedlander ML; Hedley DW; Swanson C; Russell P
J Clin Oncol; 1988 Feb; 6(2):282-90. PubMed ID: 3276825
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of DNA content in epithelial ovarian cancer.
Gajewski WH; Fuller AF; Pastel-Ley C; Flotte TJ; Bell DA
Gynecol Oncol; 1994 Apr; 53(1):5-12. PubMed ID: 8175021
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage.
Lage JM; Weinberg DS; Huettner PC; Mark SD
Cancer; 1992 Jun; 69(11):2668-75. PubMed ID: 1571896
[TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
[TBL] [Abstract][Full Text] [Related]
5. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors.
Kühn W; Kaufmann M; Feichter GE; Rummel HH; Schmid H; Heberling D
Gynecol Oncol; 1989 Jun; 33(3):360-7. PubMed ID: 2722063
[TBL] [Abstract][Full Text] [Related]
6. Influence of cellular DNA content on survival in advanced ovarian cancer.
Friedlander ML; Hedley DW; Taylor IW; Russell P; Coates AS; Tattersall MH
Cancer Res; 1984 Jan; 44(1):397-400. PubMed ID: 6690054
[TBL] [Abstract][Full Text] [Related]
7. Tumor DNA content as a prognostic feature in advanced epithelial ovarian carcinoma.
Blumenfeld D; Braly PS; Ben-Ezra J; Klevecz RR
Gynecol Oncol; 1987 Jul; 27(3):389-402. PubMed ID: 3623235
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy.
Friedlander ML; Russell P; Taylor IW; Hedley DW; Tattersall MH
Pathology; 1984 Jul; 16(3):301-6. PubMed ID: 6514398
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients.
Baak JP; Schipper NW; Wisse-Brekelmans EC; Ceelen T; Bosman FT; van Geuns H; Wils J
Br J Cancer; 1988 May; 57(5):503-8. PubMed ID: 3395555
[TBL] [Abstract][Full Text] [Related]
10. Influence of cellular DNA content on disease-free survival of Stage II breast cancer patients.
Hedley DW; Rugg CA; Ng AB; Taylor IW
Cancer Res; 1984 Nov; 44(11):5395-8. PubMed ID: 6488193
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of nuclear DNA content in malignant epithelial tumors of the ovary.
Brescia RJ; Barakat RA; Beller U; Frederickson G; Suhrland MJ; Dubin N; Demopoulos RI
Cancer; 1990 Jan; 65(1):141-7. PubMed ID: 2293860
[TBL] [Abstract][Full Text] [Related]
12. Influence of cellular DNA content on survival in ovarian carcinoma.
Klemi PJ; Joensuu H; Mäenpää J; Kiilholma P
Obstet Gynecol; 1989 Aug; 74(2):200-4. PubMed ID: 2748056
[TBL] [Abstract][Full Text] [Related]
13. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
14. [Flow cytometric analysis of DNA ploidy pattern in advanced gastric cancer and its relationship with prognosis].
Kimura H; Yonemura Y; Iwasa K; Ohyama S; Kosaka T; Miwa K; Miyazaki I
Nihon Geka Gakkai Zasshi; 1991 Mar; 92(3):288-92. PubMed ID: 2051980
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers: results of RTOG 91-08.
Fu KK; Hammond E; Pajak TF; Clery M; Doggett RL; Byhardt RW; McDonald S; Cooper JS
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):661-71. PubMed ID: 7913703
[TBL] [Abstract][Full Text] [Related]
16. Cellular DNA content and survival in advanced ovarian carcinoma.
Pfisterer J; Kommoss F; Sauerbrei W; Renz H; du Bois A; Kiechle-Schwarz M; Pfleiderer A
Cancer; 1994 Nov; 74(9):2509-15. PubMed ID: 7923008
[TBL] [Abstract][Full Text] [Related]
17. Proposal for therapeutic approach based on prognostic factors including morphometric and flow-cytometric features in stage III-IV ovarian cancer.
Wils J; van Geuns H; Baak J
Cancer; 1988 May; 61(9):1920-5. PubMed ID: 3355983
[TBL] [Abstract][Full Text] [Related]
18. [DNA ploidy and results of first line chemotherapy in ovarian cancer patients].
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Debniak J
Ginekol Pol; 2006 Aug; 77(8):589-96. PubMed ID: 17076189
[TBL] [Abstract][Full Text] [Related]
19. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance.
Hedley DW; Friedlander ML; Taylor IW
Cytometry; 1985 Jul; 6(4):327-33. PubMed ID: 4017799
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study.
Veerman MM; van der Wurff AA; van de Water M; Kruitwagen RF; Feijen HW; Vos MC
Int J Gynecol Pathol; 2009 Sep; 28(5):432-41. PubMed ID: 19696612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
